<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Stages of secondary mitral regurgitation</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Stages of secondary mitral regurgitation</h1>
<div class="graphic"><div class="figure"><div class="ttl">Stages of secondary mitral regurgitation</div><div class="cntnt"><table cellspacing="0"><colgroup width="5%"></colgroup> <colgroup width="11%"></colgroup> <colgroup span="4" width="21%"></colgroup> <tbody> <tr> <td class="subtitle1">Grade</td> <td class="subtitle1">Definition</td> <td class="subtitle1">Valve anatomy</td> <td class="subtitle1">Valve hemodynamics*</td> <td class="subtitle1">Associated cardiac findings</td> <td class="subtitle1">Symptoms</td> </tr> <tr> <td class="centered"><strong>A</strong></td> <td><strong>At risk of MR</strong></td> <td> <ul> <li>Normal valve leaflets, chords, and annulus in a patient with coronary disease or cardiomyopathy</li> </ul> </td> <td> <ul> <li>No MR jet or small central jet area &lt;20% LA on Doppler</li> <li>Small vena contracta &lt;0.30 cm</li> </ul> </td> <td> <ul> <li>Normal or mildly dilated LV size with fixed (infarction) or inducible (ischemia) regional wall motion abnormalities</li> <li>Primary myocardial disease with LV dilation and systolic dysfunction</li> </ul> </td> <td> <ul> <li>Symptoms due to coronary ischemia or HF may be present that respond to revascularization and appropriate medical therapy</li> </ul> </td> </tr> <tr> <td class="centered"><strong>B</strong></td> <td><strong>Progressive MR</strong></td> <td> <ul> <li>Regional wall motion abnormalities with mild tethering of mitral leaflet</li> <li>Annular dilation with mild loss of central coaptation of the mitral leaflets</li> </ul> </td> <td> <ul> <li>ERO &lt;0.40 cm<sup>2</sup><sup>¶</sup></li> <li>Regurgitant volume &lt;60 mL</li> <li>Regurgitant fraction &lt;50%</li> </ul> </td> <td> <ul> <li>Regional wall motion abnormalities with reduced LV systolic function</li> <li>LV dilation and systolic dysfunction due to primary myocardial disease</li> </ul> </td> <td> <ul> <li>Symptoms due to coronary ischemia or HF may be present that respond to revascularization and appropriate medical therapy</li> </ul> </td> </tr> <tr> <td class="centered"><strong>C</strong></td> <td><strong>Asymptomatic severe MR</strong></td> <td> <ul> <li>Regional wall motion abnormalities and/or LV dilation with severe tethering of mitral leaflet</li> <li>Annular dilation with severe loss of central coaptation of the mitral leaflets</li> </ul> </td> <td> <ul> <li>ERO ≥0.40 cm<sup>2</sup><sup>¶</sup></li> <li>Regurgitant volume ≥60 mL</li> <li>Regurgitant fraction ≥50%</li> </ul> </td> <td> <ul> <li>Regional wall motion abnormalities with reduced LV systolic function</li> <li>LV dilation and systolic dysfunction due to primary myocardial disease</li> </ul> </td> <td> <ul> <li>Symptoms due to coronary ischemia or HF may be present that respond to revascularization and appropriate medical therapy</li> </ul> </td> </tr> <tr> <td class="centered"><strong>D</strong></td> <td><strong>Symptomatic severe MR</strong></td> <td> <ul> <li>Regional wall motion abnormalities and/or LV dilation with severe tethering of mitral leaflet</li> <li>Annular dilation with severe loss of central coaptation of the mitral leaflets</li> </ul> </td> <td> <ul> <li>ERO ≥0.40 cm<sup>2</sup><sup>¶</sup></li> <li>Regurgitant volume ≥60 mL</li> <li>Regurgitant fraction ≥50%</li> </ul> </td> <td> <ul> <li>Regional wall motion abnormalities with reduced LV systolic function</li> <li>LV dilation and systolic dysfunction due to primary myocardial disease</li> </ul> </td> <td> <ul> <li>HF symptoms due to MR persist even after revascularization and optimization of medical therapy</li> <li>Decreased exercise tolerance</li> <li>Exertional dyspnea</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>MR: mitral regurgitation; LA: left atrium; LV: left ventricle; HF: heart failure; ERO: effective regurgitant orifice; 2D: two-dimensional; TTE: transthoracic echocardiogram.</p>
<p>* Several valve hemodynamic criteria are provided for assessment of MR severity, but not all criteria for each category will be present in each patient. Categorization of MR severity as mild, moderate, or severe depends on the data quality and integration of these parameters in conjunction with other clinical evidence.</p>
    
    ¶ The measurement of the proximal isovelocity surface area by 2D TTE in patients with secondary MR underestimates the true ERO because of the crescentic shape of the proximal convergence. Thus, the 2017 American Society of Echocardiography recommendations for native valvular regurgitation note that the criterion for severe secondary MR may be ≥0.30 cm<sup>2</sup> in the presence of an elliptical regurgitant orifice area.</div><div class="graphic_reference"><p>Reproduced from: Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2017; 70:252. Table used with the permission of Elsevier Inc. All rights reserved.</p>
    
    The content within this table is still current as of the 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease.</div><div id="graphicVersion">Graphic 114438 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
